What is Beryl Drugs share price and what are the returns for Beryl Drugs share?

Beryl Drugs share price is Rs 23.50 as on 16 Jun, 2026, 03:40 PM IST.

What has been highest price of Beryl Drugs share in last 52 weeks?

52 Week high of Beryl Drugs share is Rs 30.00 while 52 week low is Rs 15.92

What's the market capitalization of Beryl Drugs?

Beryl Drugs share has a market capitalization of Rs 11.92 Cr. Within Pharmaceuticals sector, it's market cap rank is 178.

What is the PE & PB ratio of Beryl Drugs?

The PE ratio of Beryl Drugs stands at 28.06, while the PB ratio is 1.21.

Beryl Drugs Share Price

23.500.00 (0.00%)

BSE

Closed
As On:
As On: 16 Jun, 2026, 03:40 PM IST

Sector: Pharmaceuticals
Industry: Pharma - Indian

STOCK SCORE

Unlock Scores

1D
1W
1M
3M
6M
1Y
5Y

Loading...

Try ETMarkets GPTNEW

Open	-
High	-
Low	-
Prev Close	-
Volume	-
VWAP(₹)	-

Share Price	Value
Today/Current/Last	-23.50
Previous Day	-23.50

Beryl Drugs Share Recommendations

No Recommendations details available for this stock.
Check out other stock recos.

News & Analysis

View all Beryl Drugs Share News & Announcements

Share Analysis

EARNINGS

FUNDAMENTAL

RELATIVE VALUATION

RISK

PRICE MOMENTUM

Unlock Stock Score, Analyst' Ratings & Recommendations

Score on 10-point scale
Ratings by analysts
Stock performance

JOIN ET PRIME

Financials

Income (P&L)

Quarterly	Mar 2018	Dec 2017	Sep 2017	Jun 2017	Mar 2017
Total Income	4.73	3.63	3.24	4.88	2.51
Total Income Growth (%)	30.22	12.18	-33.68	94.43	-17.21
Total Expenses	3.76	3.48	3.09	4.78	2.47
Total Expenses Growth (%)	7.96	12.57	-35.32	93.95	-13.79
EBIT	0.97	0.15	0.15	0.10	0.05
EBIT Growth (%)	534.64	4.14	41.83	119.41	-72.96
Profit after Tax (PAT)	0.88	0.10	0.54	0.03	-0.02
PAT Growth (%)	755.76	-81.13	1,468.21	-	-119.67
EBIT Margin (%)	20.60	4.23	4.55	2.13	1.89
Net Profit Margin (%)	18.52	2.82	16.75	0.71	-0.80
Basic EPS (₹)	1.73	0.20	0.16	0.00	0.00

	Mar 2026	Dec 2025	Sep 2025	Jun 2025	Mar 2025
Total Income	5.47	3.85	5.16	4.84	5.22
Total Income Growth (%)	42.00	-25.33	6.63	-7.35	-3.39
Total Expenses	4.53	4.37	4.82	4.67	5.04
Total Expenses Growth (%)	3.75	-9.34	3.23	-7.41	-1.62
EBIT	0.94	-0.52	0.34	0.17	0.18
EBIT Growth (%)	-	-251.57	99.59	-5.64	-35.64
Profit after Tax (PAT)	0.56	-0.17	0.01	0.02	0.15
PAT Growth (%)	-	-1,984.27	-57.82	-86.11	191.00
EBIT Margin (%)	17.14	-13.40	6.60	3.53	3.46
Net Profit Margin (%)	10.29	-4.36	0.17	0.44	2.91
Basic EPS (₹)	1.11	-0.33	0.02	0.04	0.30

	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Total Revenue	19.31	22.55	27.12	27.16	14.77
Total Revenue Growth (%)	-14.39	-16.85	-0.12	83.88	3.42
Total Expenses	18.72	21.69	26.12	26.17	15.72
Total Expenses Growth (%)	-13.68	-16.95	-0.22	66.50	9.28
Profit after Tax (PAT)	0.42	0.58	0.77	0.77	-0.66
PAT Growth (%)	-26.61	-24.69	0.34	-	-375.02
Operating Profit Margin (%)	4.82	6.59	5.51	5.20	-3.51
Net Profit Margin (%)	2.19	2.73	2.87	2.84	-4.51
Basic EPS (₹)	0.84	1.14	1.52	1.52	-1.30

Insights

Employee & Interest Expense
Company has spent 1.78% of its operating revenues towards interest expenses and 13.1% towards employee cost in the year ending Mar 31, 2026. (Source: Standalone Financials)

View Details

Balance Sheet

Annual	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Total Assets	14.96	15.96	17.49	17.51	17.82
Total Assets Growth (%)	-6.27	-8.75	-0.11	-1.74	-4.45
Total Liabilities	5.08	6.46	8.56	9.45	10.53
Total Liabilities Growth (%)	-21.36	-24.53	-9.42	-10.26	-1.77
Total Equity	9.89	9.50	8.92	8.07	7.29
Total Equity Growth (%)	4.11	6.50	10.53	10.70	-8.07
Current Ratio (x)	1.55	2.10	1.78	1.63	1.25
Total Debt to Equity (x)	0.24	0.43	0.57	0.56	0.73
Contingent Liabilities	0.00	0.85	0.77	2.02	1.36

No Data Available

View Details

Cash Flows

Annual	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Net Cash flow from Operating Activities	3.65	2.64	0.82	2.48	-0.29
Net Cash used in Investing Activities	-2.16	-0.40	-1.08	-1.30	0.54
Net Cash flow from Financing Activities	-2.03	-1.55	0.10	-1.17	-0.43
Net Cash Flow	-0.54	0.69	-0.16	0.01	-0.18
Closing Cash & Cash Equivalent	0.27	0.81	0.12	0.28	0.27
Closing Cash & Cash Equivalent Growth (%)	-66.41	551.96	-55.88	4.31	-39.97
Total Debt/ CFO (x)	0.66	1.54	6.21	1.83	-18.46

No Data Available

Insights

Increase in Cash from Investing
Company has used Rs 2.16 cr for investing activities which is an YoY increase of 444.8%. (Source: Standalone Financials)

View Details

Ratios

Annual	FY 2018
Return on Equity (%)	0.00
Return on Capital Employed (%)	0.00
Return on Assets (%)	0.00
Interest Coverage Ratio (x)	10.28
Asset Turnover Ratio (x)	0.00
Price to Earnings (x)	-
Price to Book (x)	0.00
EV/EBITDA (x)	0.00
EBITDA Margin (%)	10.56

Annual	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Return on Equity (%)	4.29	6.09	8.61	9.49	-9.03
Return on Capital Employed (%)	8.93	11.96	12.55	12.51	-5.50
Return on Assets (%)	2.83	3.62	4.39	4.37	-3.69
Interest Coverage Ratio (x)	7.04	4.99	5.77	5.33	1.31
Asset Turnover Ratio (x)	1.25	1.26	1.53	1.52	0.80
Price to Earnings (x)	23.15	18.55	19.46	8.09	-8.08
Price to Book (x)	0.99	1.13	1.67	0.77	0.73
EV/EBITDA (x)	4.92	5.29	7.41	4.59	18.06
EBITDA Margin (%)	12.56	12.48	10.00	8.23	3.92

Found Financials useful?

5 Days	14 Days	28 Days
-	-	-

Peer Comparison

Ratio Performance

NAME	P/E (x)	P/B (x)	ROE %	ROCE %	ROA %	Rev CAGR [3Yr]	OPM	NPM	Basic EPS	Current Ratio	Total Debt/ Equity (x)	Total Debt/ CFO (x)
Beryl Drugs	28.06	1.21	0.00	0.00	0.00	-10.64	8.50	6.21	1.96	0.00	0.00	0.66
Zenith Health	3,350.78	2.30	0.06	0.33	0.04	-6.73	0.23	0.04	0.01	2.09	0.00	0.00
Chemo Pharma	-1.39	12.79	-919.20	-914.65	-654.32	22.77	-2,255.07	-2,255.27	-79.03	3.50	0.00	0.00
Avon Lifesciences	-3.12	0.30	-65.59	-7.79	-8.80	-24.66	-9.97	-33.73	-15.47	1.10	3.23	25.51
Colinz Labs	28.40	1.45	5.12	7.32	4.02	-3.29	11.98	8.38	2.04	3.68	0.04	0.15
Add More

Annual Ratios (%)

Choose from Peers

Ortin Labs
Norris Medicine
Unjha Form
Kamron Labs.
Vivanza Biosciences

Choose from Stocks

Stock Performance

CHART
TABLE

1D
1W
1M
3M
6M
1Y
5Y

Choose from Peers
Choose from Stocks

NAME	1D	1W	1M	3M	1Y	3Y	5Y
Beryl Drugs Stock Performance	0.00	13.53	-4.86	8.49	17.56	67.86	119.42
Zenith Health Stock Performance	0.00	-2.45	0.95	-4.79	-29.80	-22.06	-62.32
Chemo Pharma Stock Performance	1.38	-0.90	1.85	11.11	-15.51	198.99	285.96
Avon Lifesciences Stock Performance	1.85	0.00	120.07	127.68	142.80	157.03	9.67
Colinz Labs Stock Performance	3.09	27.49	20.35	16.02	7.13	60.03	317.94
Add More

Category	No. of Shares	Percentage	% Change QoQ
Promoters	13,93,614	27.48 %	1.10
Pledge	0	0.00 %	0.00
Others	36,78,086	72.52 %	-1.10

Category	Mar 2026	Dec 2025	Sep 2025	Jun 2025
Promoters	27.48	26.38	26.38	26.38
Pledge	0.00	0.00	0.00	0.00
FII	0.00	0.00	0.00	0.00
DII	0.00	0.00	0.00	0.00
Mutual Funds	0.00	0.00	0.00	0.00
Others	72.52	73.62	73.62	73.62

Mutual Funds Ownership

No Data Available

Corporate Actions

Recent
Board Meeting
Others
Jun 08, 2026
Board Meeting
Audited Results
May 20, 2026
General Meeting
-
Apr 01, 2026

Board Meetings

Announced on	Meeting on
Jun 08, 2026	Jun 16, 2026
Others
May 20, 2026	May 28, 2026
Audited Results
Mar 20, 2026	Apr 01, 2026
Notice of EGM & Others
Feb 01, 2026	Feb 09, 2026
Quarterly Results
Dec 23, 2025	Jan 03, 2026
Others

Dividends
Announced on Ex-Date Dividend%
Sep 07, 2002 Aug 23, 2002 0%
Bonus
No Data Available
Splits
No Data Available
Rights
No Data Available
AGM/EGM Meetings
Announced on Meeting on
Apr 01, 2026 May 11, 2026
-
Sep 02, 2025 Sep 30, 2025
-
Sep 09, 2024 Sep 30, 2024
A.G.M.
Aug 25, 2023 Sep 21, 2023
A.G.M.
Nov 11, 2020 -
Book closure from Dec 16, 2020 to Dec 23, 2020

Announced on	Ex-Date	Dividend%
Sep 07, 2002	Aug 23, 2002	0%

Announced on	Meeting on
Apr 01, 2026	May 11, 2026
-
Sep 02, 2025	Sep 30, 2025
-
Sep 09, 2024	Sep 30, 2024
A.G.M.
Aug 25, 2023	Sep 21, 2023
A.G.M.
Nov 11, 2020	-
Book closure from Dec 16, 2020 to Dec 23, 2020

About Beryl Drugs

Beryl Drugs Ltd., incorporated in the year 1993, is a Small Cap company (having a market cap of Rs 11.92 Crore) operating in Pharmaceuticals sector.

Beryl Drugs Ltd. key Products/Revenue Segments include Pharmaceuticals and Scrap for the year ending 31-Mar-2025.

For the quarter ended 31-03-2026, the company has reported a Standalone Total Income of Rs 5.47 Crore, up 42.00 % from last quarter Total Income of Rs 3.85 Crore and up 4.75 % from last year same quarter Total Income of Rs 5.22 Crore. Company has reported net profit after tax of Rs .56 Crore in latest quarter.

The company’s top management includes Mr.Sudhir Sethi, Mr.Sanjay Sethi, Mr.Abhinav Naik, Mrs.Shreya Saraf, Mr.Ashish Baraskar, Mrs.Neha Sharma. Company has Prateek Jain & Co. as its auditors. As on 31-03-2026, the company has a total of .51 Crore shares outstanding.

Beryl Drugs Share Price Today is Rs. 23.50. On previous day, the Beryl Drugs Share Price (NSE) closed at Rs. 23.5, featuring among the most traded securities on the National Stock Exchange.

Shareholdings:
As of 31st Mar, 2026, the promoter held 27.48% of the stake in Beryl Drugs shares, out of which 0.0% was pledged. On the same date, foreign institutional investors' (FII) holdings of Beryl Drugs stocks was 0.0% as compared to 0.0% in Dec 2025 with null of 0.0%. The domestic institutional investors (DII) holdings on 31st Mar, 2026 was 0.0% as compared to 0.0% in Dec 2025 with null of 0.0%. Out of the total DII holdings in Beryl Drugs shares 0.0% was held by mutual funds. The rest including public held is 0.0%. Beryl Drugs stock price is reflected on both the exchanges - BSE and NSE.

Dividend, Bonus & Split Information:
Beryl Drugs Dividend: Ever since 1993, Beryl Drugs dividends has been paid out around 1 times. As on 16 Jun, 2026, 03:40 PM IST, The overall dividend yield for Beryl Drugs stands at 0.0%. The last dividend paid was on August 23, 2002 (Rs. 0.0). The Earnings Per Share (EPS) for quarter ending 31st Mar 2026 is Rs. 0.84.

Beryl Drugs Bonus: The most recent bonus issue had been in year null around 0 years ago at 0 : 0 ratio. The first bonus issue was announced in null.

Stock Forecast:
After showing 5.81 Cr. of sales and 50.78% of quarterly net profit, there have been multiple ups and downs in the Beryl Drugs stock prices in the past few weeks. For example, Beryl Drugs stock price on 9th of June 2026 was around Rs. 24.25. Beryl Drugs share price now stands at an average of Rs. 23.50. Judging by last week's performance, stock is in down trend.

Beryl Drugs has a median target price of Rs. 0.0 in 12 months by 0 analysts. They have provided a high estimate of Rs. 0.0 and low estimate of Rs. 0.0 for Beryl Drugs share.

Historical Prices and Performance:
Beryl Drugs, incorporated in 1993 is a Small Cap company (with a market cap of Rs. 11.92) operating in Pharmaceuticals sector.
The Return of Equity (ROE) in last five financial years given by Beryl Drugs stock was 4.29%, 6.09%, 8.61%, 9.49% and -9.03% respectively.
The Beryl Drugs share gave a 3 year return of 44.08% as compared to Nifty 50 which gave a return of 27.43%.
Beryl Drugs announced 0.0% final dividend on August 23, 2002.

Key Metrics:
PE Ratio of Beryl Drugs is 28.06
Prices/Sales Ratio of Beryl Drugs is 0.0
Price/Book Ratio of Beryl Drugs is 1.21

Peer Insights:
Peers are businesses with comparable activities, buisness objectives and affiliation with a particular industry area. The PE ratio and PB Ratio of the company are among its competitors stand at 28.06 and 1.21 respectively.

Leadership of Beryl Drugs :
Ashish Baraskar is Chief Financial Officer
Neha Sharma is Co. Secretary & Compl. Officer
Sudhir Sethi is Chairman & Director
Sanjay Sethi is Managing Director
Abhinav Naik is Independent Director
Shreya Saraf is Independent Woman Director

Industry

Pharma - Indian

Key Indices Listed On

-

Address

133, Kanchan Bagh,Indore, Madhya Pradesh - 452001

Contact

beryldrugs25@yahoo.com

http://www.beryldrugs.com

PE Ratio(x)	28.06
EPS - TTM(₹)	0.84
MCap(₹ Cr.)	11.92
MCap Rank	178
PB Ratio(x)	1.21
Div Yield(%)	-
Face Value(₹)	10.00
52W High(₹)	30.00
52W Low(₹)	15.92
MCap/Sales	-
Beta(1 Month)	0.72
BV/Share(₹)	19.50

1 Day	0.0%
1 Month	11.11%
3 Months	22.01%
1 Year	20.51%
3 Years	44.08%
5 Years	206.39%

R1	-	Pivot -	S1	-
R2	-		S2	-
R3	-		S3	-

Beryl Drugs Share Price

Key Metrics